Tagged with Switzerland,

Switzerland Taken from the recently published Swiss Biotech Report 2023, these figures cover major public and private financing transactions in Swiss biotech in the past year; major financing categories; capital investments in Swiss biotech companies; revenues, R&D expenses, profit/loss and liquidity; as well as well as the total number of biotech…

Switzerland An extract from PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on price controls and reference pricing systems in Switzerland. Buy The Pharma Legal Handbook: Market Access & HTA – Switzerland here for £359.   1.1 How does price control at…

Global The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive Director Charles Gore outlines the MPP’s goals, how it interacts with an industry – innovative pharma – known to jealously…

Switzerland The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over five million more likely to follow. Elsewhere, Swiss health insurance premiums are set to see their largest rise since 2010…

Switzerland Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its long-time CEO resign. But make no mistake: the Swiss giant is carefully guarding its position as one of the world’s…

Switzerland After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment from Takeda. “Switzerland is a globally recognized hotspot for biopharma companies. As such, it naturally attracts investments. Our role is…

Switzerland Lonza’s global head of Mammalian Biologics, Jennifer Cannon, talks about disruption in the CDMO industry, explains how the Swiss giant is reimagining new models based on risk-sharing, and goes through the effects of the pandemic on both the company and the industry, including supply chain disruption, demand for new capabilities…

Global Exactly five months after concluding that it was the right time to “monetize” its investment in a cross-town rival – providing Roche “full strategic flexibility” in the process – Novartis has announced a major restructuring; this time, too, citing financial motives.   The Swiss giant – fifth in the global…

Global As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities: supporting country readiness, contributing to equitable distribution, and driving innovation.   From the early days…

Switzerland Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the top five markets within the continent in order to introduce four or five new products from their pipeline in the…

Global Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being done on patient engagement and expectation management for the firm’s cutting-edge CAR-T therapies, and how a stronger patient voice can…

Switzerland Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.   Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this…